Today's Change
+0%
AI Sentiment
62%
Sector AnalysisLive data
Materials Sector Outlook
The Materials sector is up 0% today with bullish sentiment across 2 recent news articles.
Bullish Factors
- No strong bullish signals detected
Risk Factors
- No strong bearish signals detected
Stocks in Materials
0 stocks| Symbol | Company | Change |
|---|
Materials News
928 articlesGlobeNewswire Inc.65d ago
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Benzinga65d ago
U.S. GoldMining Mobilizes 2026 Exploration Program Targeting District-Scale Potential at the Whistler Project, Alaska
GlobeNewswire Inc.65d ago
USA Rare Earth Announces Definitive Agreement to Acquire Serra Verde Group for ~$2.8 Billion, Creating the Global Rare Earth Leader
GlobeNewswire Inc.65d ago
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
GlobeNewswire Inc.65d ago
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
GlobeNewswire Inc.65d ago
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
GlobeNewswire Inc.65d ago
Bombardier and Vista Sign Service Agreement Focused on Smart Parts Programs
GlobeNewswire Inc.65d ago
Bombardier et Vista signent une entente de services axée sur les programmes Smart Parts
GlobeNewswire Inc.65d ago
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
GlobeNewswire Inc.65d ago
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
GlobeNewswire Inc.65d ago
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
GlobeNewswire Inc.66d ago
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Market Sentiment
Bullish
62% Sentiment Score
Sector Stats
Total Stocks0
News Today2
Avg Volume0
AI SentimentBullish